Summary
The pharmacokinetic properties of a single oral dose of 100 mg of tiapride were studied in six patients with Huntington's disease.
The results for five patients were consistent with a two compartment open model. Peak plasma concentrations were observed within 2 h following durg administration with a mean value of 0.92 μg/ml being recorded.
The drug was rapidly eliminated as unmetabolised tiapride in the urine, 51% of the dose was recovered in 24 h. The plasma elimination half-life was 5.3 h and the average apparent plasma clearance was 16.6 l/h.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Buruma OJS, Roos RAC, Bruyn GW, Kemp B, vander Velde EA (1982) Tiapride in the treatment of tardive dyskinesia. Acta Neurol Scand 65: 38–44
Elliott PNC, Jenner P, Huizing G, Marsden CD, Miller R (1977) Substituted benzamides as cerebral dopamine antagonists in rodents. Neuropharmacol 16: 333–342
Greil W, Auberger S, Haag H, Ruther E (1985) Tiapride: Effects on tardive dyskinesia and on prolactin plasma concentrations. Neuropsychobiology 14: 17–22
Jenner P, Elliott PNC, Clow A, Reavill C, Marsden CD (1978) A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs. J Pharm Pharmacol 30: 46–48
Lees AJ, Lander CM, Stern GM (1979) Tiapride in levodopa-induced involuntary movements. J Neurol Neurosurg Psychiat 42: 380–383
Lhermitte F, Signoret JL, Agid Y (1977) Etude des effects d'une molecule originale, le tiapride, dans le traitement des mouvements anormaux d'origine extrapyramidale. Sem Hop Paris 53: 9–15
Metzler CM (1969) NONLIN: A computer program for parameter estimiation in nonlinear situations. Technical report 7292/69/7292/005. The Upjohn Co, Kalamazoo. Mich.
Nielsen BM (1983) Tiapride in levodopa-induced involuntary movements. Acta Neurol Scand 67: 372–375
Norman TR, James RH, Gregory MS (1986) Determination of tiapride in plasma by high-performance liquid chromatography. J Chromatogr 375: 197–201
Price P, Parkes JD, Marsden CD (1978) Tiapride in parkinson's disease. Lancet 2: 1106
Rey E, d'Athis Ph, Richard MO, de Lautre D, Olive G (1982) Pharmacokinetics of tiapride and absolute bioavailability of three extravascular forms. Int J Clin Pharmacol Therap Toxicol 20: 62–67
Roos RAC, Buruma OJ, Bruyn GW, Kemp B, vander Velde EA (1982) Tiapride in the treatment of Huntington's chorea. Acta Neurol Scand 65: 45–50
Roos RAC, deHaas EJM, Buruma OJS, de Wolff FA (1986) Pharmacokinetics of tiapride in patients with tardive dyskinesia and Huntington's Disease. Eur J Clin Pharmacol 31: 191–194
Sedman AJ, Wagner JG (1974) AUTOAN: A decision making pharmacokinetic computer program. Publication Distribution Service, Ann Arbor, Mich
SPSS Inc (1986) SPSSX users guide (2nd edn) McGraw Hill
Strolin-Benedetti M, Donath A, Frigerio A, Morgan KT, Laville C, Malnoe A (1978) Absorption, elimination et metabolisme du tiapride (FLO 1347), medicament neuroleptique chez le rat, le chien et l'homme. Ann Pharm Fr 36: 279–288
Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Interlligence Publications Illinois, USA
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Norman, T., Chiu, E., James, R.H. et al. Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease. Eur J Clin Pharmacol 32, 583–586 (1987). https://doi.org/10.1007/BF02455992
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02455992